von Tobias Borgers | Sep. 28, 2021 | Markt
Maersk has been providing global pharmaceutical players in Central Europe professional warehousing and distribution services since 2001, specifically tailored to meet the needs of this demanding customer segment. Building further on its experience and to address...
von Tobias Borgers | Sep. 28, 2021 | Bayer
Danish biotech Gubra will help German neighbor Bayer find new peptide treatments for kidney and heart disorders in a biobucks deal worth up to 216 million euros ($253 million). The Big Pharma will collaborate with Gubra on researching potential drugs for cardiorenal...
von Tobias Borgers | Sep. 23, 2021 | Bayer
Über Finerenon Finerenon (BAY 94-8862) ist ein nicht-steroidaler und selektiver Antagonist des Mineralokortikoid-Rezeptors (MR), der in präklinischen Studien gezeigt hat, dass er schädliche Wirkungen einer Überaktivierung des Mineralokortikoid-Rezeptors (MR) hemmt. Es...
von Tobias Borgers | Sep. 23, 2021 | Boehringer
Boehringer Ingelheim eröffnet am 6. Oktober eine biopharmazeutische Produktionsanlage in Wien.Wien (OTS) – Nach rund vier Jahren Bauzeit eröffnet Boehringer Ingelheim an seinem Standort in Wien-Meidling eine neue biopharmazeutische Produktionsanlage. Darin...
von Tobias Borgers | Sep. 21, 2021 | Bayer
In a bid to quickly broaden its drug discovery abilities, Bayer (BAYRY) has reached a deal to acquire Vividion Therapeutics for $1.5 billion, the third time in two years the company has bought a small biotech with proprietary technology for uncovering...
